Margenza Injection, Solution, Concentrate
Product Images NDC 74527-022

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Margenza (NDC 74527-022). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macrogenics, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Margenza 01)

A Kaplan-Meier survival curve graph showing progression-free survival probability over time in months since initial randomization. It compares two treatment groups: margetuximab plus chemotherapy (solid line) and trastuzumab plus chemotherapy (dotted line). The graph includes patient-at-risk counts at various time points and marks censoring events with plus signs.*

FDA Label Image

Principal Display Panel (250 mg/10 mL Vial Carton)

MARGENZA 250 mg/10 mL (25 mg/mL) injection, solution concentrate for intravenous infusion after dilution. Single-dose vial label showing the proprietary name MARGENZA, generic name margetuximab-cmkb, dosage strength, and administration route. The label also includes storage instructions, contents, and manufacturer MacroGenics, Inc. Barcode and NDC 74527-022-02 are visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.